April 29, 2024 – Talk Bio

Actionable Insights Powered by AI

Addex Therapeutics’ Phase II Epilepsy Drug in Partnership with J&J Fails to Meet Endpoints

12 months ago talkbio0Tagged Clinical, development aspects, drug candidate, Epilepsy, J&J, Phase 2 Clinical Trials

Addex Therapeutics, J&J, Phase II trial, epilepsy, drug candidate, clinical endpoints, future development.

Pfizer’s Revolutionary Hemophilia B Gene Therapy Gains FDA Approval and Introduces Unique Warranty Program

12 months ago talkbio0Tagged Approved, Biotechnology, Blood coagulation, gene therapy, Health care facility, Hemophilia B, Hereditary Diseases, Pfizer, United States Food and Drug Administration

Pfizer, FDA, Hemophilia B, Gene Therapy, Approval, Warranty, Treatment, Genetic Disorder, Blood Clotting, Healthcare, Biotechnology

AbbVie’s Skyrizi and Rinvoq Drive Growth, Counteracting Humira Decline

12 months ago talkbio0Tagged AbbVie, Drug Industry, drug sales, full-year outlook, Immunology, revenue growth, Rinvoq, Skyrizi

AbbVie, Skyrizi, Rinvoq, Humira, full-year outlook, pharmaceutical industry, revenue growth, drug sales, immunology drugs